NewGene Ltd. Achieves Certification to Provide NimbleGen Sequence Capture Services in UK

PENZBERG, Germany--(BUSINESS WIRE)-- Roche NimbleGen (SWX:RO)(SWX:ROG)(Pink Sheets:RHHBY) announces that Newcastle-based genomic services provider NewGene Ltd. has officially become a Certified Service Provider (CSP) for NimbleGen Sequence Capture. They will provide services for NimbleGen Sequence Capture Arrays with sequencing on the Genome Sequencer FLX System from 454 Life Sciences, a Roche Company. NewGene Ltd. has passed a comprehensive certification test plan to officially become a member of the Roche NimbleGen Certified Service Provider network. They will process customer gDNA samples for genomic enrichment, using the complete NimbleGen Sequence Capture Array workflow optimized for 454 GS FLX Titanium Series sequencing.

“NewGene is very excited to be entering into this collaboration with Roche NimbleGen as its UK-based certified service provider. The ability to couple NimbleGen Sequence Capture technology with our next generation sequencing capabilities will provide significant scientific, technical and economic benefits to our UK customers” said David Huntley, CEO at NewGene Ltd.

“Roche NimbleGen welcomes NewGene Ltd. as our first certified service provider in the United Kingdom. NewGene’s highly skilled professionals and use of the latest next generation sequencing technologies, including our Sequence Capture arrays, will make this powerful technique widely available to researchers throughout the UK " said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit www.nimblegen.com

About NewGene
Based in Newcastle upon Tyne, NewGene is a partnership between the Newcastle Hospitals NHS Foundation Trust and Newcastle University. NewGene is a molecular diagnostics and research services company that is pioneering the use of next generation sequencing (454 Life Sciences, a Roche Company) and genotyping technologies to develop and deliver clinical diagnostic assays with the aim of reducing both costs and delivery times and in turn widening the access to important future clinical diagnostics. In addition, NewGene has significant expertise in DNA sequencing of a range of organisms on the GS FLX System for researchers including target enrichment using NimbleGen Sequence Capture.

Visit www.newgene.org.uk for more information.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

For life science research only. Not for use in diagnostic procedures.

GS FLX and NIMBLEGEN are trademarks of Roche.

Other brands or product names are trademarks of their respective holders.



CONTACT:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]
or
Roche NimbleGen
Kary Staples
Phone: +1 608 218 7623
Email: [email protected]

KEYWORDS:   United Kingdom  Europe  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Pharmaceutical  Research  Medical Supplies  Science

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.